☰

Linda Liau, M.D., Ph.D. - Publications

Affiliations: 
Brain Research Institute, Neurological Surgery University of California, Los Angeles, Los Angeles, CA 
Area:
Anaplastic astrocytoma, ependymoma, ganglioma, GBM
Website:
http://faculty.bri.ucla.edu/institution/personnel?personnel_id=8887
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

109 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Fazzari E, Azizad DJ, Yu K, Ge W, Li MX, Nano PR, Kan RL, Tum HA, Tse C, Bayley NA, Haka V, Cadet D, Perryman T, Soto JA, Wick B, ... ... Liau LM, et al. Glioblastoma Neurovascular Progenitor Orchestrates Tumor Cell Type Diversity. Biorxiv : the Preprint Server For Biology. PMID 39091877 DOI: 10.1101/2024.07.24.604840  0.348
2024 Lai TJ, Sun L, Li K, Prins TJ, Treger J, Li T, Sun MZ, Nathanson DA, Liau LM, Lai A, Prins RM, Everson RG. Epigenetic induction of cancer testis antigens and endogenous retroviruses at single-cell level enhances immune recognition and response in glioma. Cancer Research Communications. PMID 38856710 DOI: 10.1158/2767-9764.CRC-23-0566  0.423
2024 Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson BM, Cloughesy TF, Liau LM, Prins RM. Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nature Communications. 15: 4800. PMID 38839763 DOI: 10.1038/s41467-024-48995-7  0.673
2024 Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson BM, Cloughesy TF, Liau LM, Prins RM. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nature Communications. 15: 3882. PMID 38719809 DOI: 10.1038/s41467-024-48073-y  0.724
2024 Patel KS, Tessema KK, Kawaguchi R, Dudley L, Alvarado AG, Muthukrishnan SD, Perryman T, Hagiwara A, Swarup V, Liau LM, Wang AC, Yong W, Geschwind DH, Nakano I, Goldman SA, et al. Single-nucleus expression characterization of non-enhancing region of recurrent high-grade glioma. Neuro-Oncology Advances. 6: vdae005. PMID 38616896 DOI: 10.1093/noajnl/vdae005  0.314
2023 Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson BM, Cloughesy TF, Liau LM, Prins RM. Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma Patients. Research Square. PMID 37790490 DOI: 10.21203/rs.3.rs-3287211/v1  0.73
2023 Sun L, Kienzler JC, Reynoso JG, Lee A, Shiuan E, Li S, Kim J, Ding L, Monteleone AJ, Owens GC, Phillips JJ, Everson RG, Nathanson D, Cloughesy TF, Li G, ... Liau LM, et al. Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors. The Journal of Clinical Investigation. 133. PMID 37655659 DOI: 10.1172/JCI169314  0.396
2023 de Godoy LL, Chawla S, Brem S, Wang S, O'Rourke DM, Nasrallah MP, Desai A, Loevner LA, Liau LM, Mohan S. Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model. Journal of Neuro-Oncology. PMID 37129737 DOI: 10.1007/s11060-023-04324-4  0.313
2022 Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, Tran DD, Ansstas G, Cobbs CS, Heth JA, Salacz ME, D'Andre S, Aiken RD, Moshel YA, Nam JY, et al. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. Jama Oncology. PMID 36394838 DOI: 10.1001/jamaoncol.2022.5370  0.317
2022 Ghochani Y, Muthukrishnan SD, Sohrabi A, Kawaguchi R, Condro MC, Bastola S, Gao F, Qin Y, Mottahedeh J, Iruela-Arispe ML, Rao N, Laks DR, Liau LM, Mathern GW, Goldman SA, et al. A molecular interactome of the glioblastoma perivascular niche reveals integrin binding sialoprotein as a mediator of tumor cell migration. Cell Reports. 41: 111511. PMID 36261010 DOI: 10.1016/j.celrep.2022.111511  0.309
2021 Lee AH, Sun L, Mochizuki AY, Reynoso JG, Orpilla J, Chow F, Kienzler JC, Everson RG, Nathanson DA, Bensinger SJ, Liau LM, Cloughesy T, Hugo W, Prins RM. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nature Communications. 12: 6938. PMID 34836966 DOI: 10.1038/s41467-021-26940-2  0.349
2021 Lee J, Uy BR, Liau LM. Brain Tumor Vaccines. Neurosurgery Clinics of North America. 32: 225-234. PMID 33781504 DOI: 10.1016/j.nec.2021.01.003  0.406
2020 Chuntova P, Chow F, Watchmaker P, Galvez M, Heimberger AB, Newell EW, Diaz A, DePinho RA, Li MO, Wherry EJ, Mitchell D, Terabe M, Wainwright DA, Berzofsky JA, Herold-Mende C, ... ... Liau LM, et al. Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Neuro-Oncology. PMID 33367885 DOI: 10.1093/neuonc/noaa277  0.327
2019 Liu F, Cox CD, Chowdhury R, Dovek L, Nguyen H, Li T, Li S, Ozer B, Chou A, Nguyen N, Wei B, Antonios J, Soto H, Kornblum H, Liau L, et al. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. Journal of Neuro-Oncology. PMID 30838489 DOI: 10.1007/S11060-019-03126-X  0.672
2019 Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, ... ... Liau LM, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature Medicine. PMID 30742122 DOI: 10.1038/S41591-018-0337-7  0.378
2019 Yao J, Nathanson D, Yong WH, Salamon N, Lai A, Leia Nghiemphu P, Prins R, Pope W, Czernin J, Everson R, Liau L, Cloughesy T, Ellingson B. NIMG-60. IDH MUTANT GLIOMAS WITH 1p/19q CO-DELETION ARE LESS ACIDIC THAN NON-CO-DELETED GLIOMAS AS MEASURED WITH PH-WEIGHTED AMINE CEST-MRI AND AMINO ACID PET Neuro-Oncology. 21: vi174-vi175. DOI: 10.1093/Neuonc/Noz175.729  0.33
2019 Sun M, Orpilla J, Contreras E, Treger J, Molaie D, Tsang J, Antonios J, Wang A, Liau L, Prins R, Everson R. IMMU-50. SYSTEMIC ADOPTIVE TRANSFER IMMUNOTHERAPY WITH TCR-TRANSDUCED T-CELLS TARGETING NY-ESO-1 FOR MENINGIOMA Neuro-Oncology. 21: vi129-vi130. DOI: 10.1093/Neuonc/Noz175.542  0.682
2019 Kienzler J, Reynoso J, Owens G, Orpilla J, Lee A, Mochizuki A, Yong WH, Liau L, Prins R. IMMU-33. IMMUNE PROFILING REVEALS INHIBITORY MACROPHAGES AND A DISTINCT SPATIAL DISTRIBUTION OF IMMUNE CELLS IN DIFFERENT TYPES OF BRAIN METASTASES Neuro-Oncology. 21: vi126-vi126. DOI: 10.1093/Neuonc/Noz175.525  0.353
2019 Lee A, Pan Y, Mochizuki A, Galvez M, Chow F, Nathanson D, Wang A, Everson R, Liau L, Xing Y, Prins R. IMMU-02. NEOANTIGENS ARISING FROM ALTERNATIVE SPLICING EVENTS MAY BE TARGETED BY TUMOR INFILTRATING LYMPHOCYTES IN GLIOBLASTOMAS Neuro-Oncology. 21: vi118-vi119. DOI: 10.1093/Neuonc/Noz175.496  0.407
2019 Fernandez E, Mai W, Bayley N, Liau L, Cloughesy T, Letai A, Nathanson D. CBMT-44. COMPREHENSIVE CHARACTERIZATION OF THE INTRINSIC APOPTOTIC MACHINERY REVEALS THE MOLECULAR BLOCKS RESPONSIBLE FOR RESISTANCE TO CELL DEATH IN GLIOBLASTOMA Neuro-Oncology. 21: vi42-vi42. DOI: 10.1093/Neuonc/Noz175.166  0.396
2019 Morrow D, Bayley N, Williams K, Muranaka H, Prins R, Liau L, Cloughesy T, Bensinger S, Nathanson D. CBMT-43. INTEGRATED LIPIDOMIC AND MOLECULAR ANALYSIS REVEALS A SUBSET OF GLIOBLASTOMA VULNERABLE TO FERROPTOSIS Neuro-Oncology. 21: vi42-vi42. DOI: 10.1093/Neuonc/Noz175.165  0.325
2019 Bayley N, Tse C, Baufeld L, Gosa L, Yan W, Zhu H, Balanis N, Cloughesy T, Liau L, Graeber T, Nathanson D. TMIC-26. PRECLINICAL MODEL SYSTEMS OF GLIOBLASTOMA REVEAL MICROENVIRONMENTAL PROGRAMS AND DEPENDENCIES IN PATIENT TUMORS Neuro-Oncology. 21: vi253-vi253. DOI: 10.1093/Neuonc/Noz175.1060  0.435
2019 Mochizuki A, Lee A, Orpilla J, Kienzler J, Galvez M, Chow F, Davidson T, Wang A, Everson R, Liau L, Cloughesy T, Prins R. TMIC-06. MYELOID POPULATIONS AND THE EFFECT OF NEOADJUVANT PD-1 INHIBITION IN THE GLIOBLASTOMA MICROENVIRONMENT: A SURFACEOMIC AND TRANSCRIPTOMIC DISSECTION AT THE SINGLE-CELL LEVEL Neuro-Oncology. 21: vi248-vi248. DOI: 10.1093/Neuonc/Noz175.1040  0.48
2019 Chow F, Mochizuki A, Lee A, Galvez M, Orpilla J, Everson R, Liau L, Cloughesy T, Prins R. ATIM-16. VALIDATION OF RESPONSE TO NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA Neuro-Oncology. 21: vi4-vi5. DOI: 10.1093/Neuonc/Noz175.016  0.424
2018 Davidson TB, Lee AH, Hsu M, Sedighim S, Orpilla J, Treger J, Mastall M, Roesch S, Rapp C, Galvez M, Mochizuki AY, Antonios JP, Garcia AJ, Kotecha N, Bayless NL, ... ... Liau LM, et al. Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30498094 DOI: 10.1158/1078-0432.Ccr-18-1176  0.683
2018 Everson RG, Antonios JP, Liau LM. Cell-Based Immunotherapy of Gliomas. Progress in Neurological Surgery. 32: 90-100. PMID 29990977 DOI: 10.1159/000469683  0.716
2018 Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of Translational Medicine. 16: 142. PMID 29843811 DOI: 10.1186/S12967-018-1507-6  0.303
2018 Cloughesy TF, Landolfi J, Vogelbaum MA, Ostertag D, Elder JB, Bloomfield S, Carter B, Chen CC, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu P, et al. Durable Complete Responses in Some Recurrent High Grade Glioma Patients Treated with Toca 511 & Toca FC. Neuro-Oncology. PMID 29762717 DOI: 10.1093/Neuonc/Noy075  0.344
2018 Cloughesy TF, Landolfi J, Vogelbaum M, Ostertag D, Elder B, Carter B, Chen CC, Kalkanis S, Kesari S, Lai A, Lee I, Liau L, Mikkelsen T, Nghiemphu L, Piccioni D, et al. Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A085  0.45
2018 Antonios JP, Soto H, Everson RG, Wang AC, Bethel J, Radu C, Ellingson B, Phelps M, Cloughesy TF, Prins RM, Liau LM. 214 Noninvasive Monitoring of Immunotherapeutic Responses in Glioblastoma Using Novel Imaging Techniques Neurosurgery. 65: 120-120. DOI: 10.1093/Neuros/Nyy303.214  0.624
2018 Bethel J, Aliche J, Orpilla J, Soto H, Everson R, Davidson T, Wang A, Liau L, Prins R. IMMU-37. VEMURAFENIB ENHANCES THE CYTOTOXICITY OF NY-ESO-1 TCR ENGINEERED T-CELLS FOR BRAF MUTANT BRAIN TUMORS Neuro-Oncology. 20: vi129-vi129. DOI: 10.1093/Neuonc/Noy148.540  0.394
2018 Mochizuki A, Orpilla J, Lee A, Garcia A, Liau L, Cloughesy T, Prins R. IMMU-28. HIGH-DIMENSIONAL SINGLE CELL CHARACTERIZATION OF THE SYSTEMIC INFLUENCE OF NEOADJUVANT PD-1 BLOCKADE IN PATIENTS WITH RECURRENT GLIOBLASTOMA Neuro-Oncology. 20: vi127-vi127. DOI: 10.1093/Neuonc/Noy148.531  0.312
2018 Lee A, Mochizuki A, Ishihara M, Garcia A, Nathanson D, Wang A, Everson R, Liau L, Prins R. IMMU-21. MULTIDIMENSIONAL CHARACTERIZATION OF IMMUNE CELL POPULATIONS IN THE GLIOMA TUMOR MICROENVIRONMENT REVEALS A DOMINANT PROPORTION OF CELLS DERIVED FROM THE MYELO-MONOCYTIC LINEAGE Neuro-Oncology. 20: vi125-vi125. DOI: 10.1093/Neuonc/Noy148.524  0.466
2018 Bayley N, Baufeld L, Gosa L, Morrow D, Tse C, Balanis N, Yan W, Cloughesy T, Liau L, Graeber T, Nathanson D. TMOD-03. GLIOMAPDOX: A MOLECULARLY DIVERSE LIBRARY OF DIRECT-FROM-PATIENT ORTHOTOPIC GLIOMA XENOGRAFTS RECAPITULATES INTRATUMOR HETEROGENEITY Neuro-Oncology. 20: vi268-vi269. DOI: 10.1093/Neuonc/Noy148.1116  0.314
2018 Antonios J, Everson R, Soto H, Khattab S, Bethel J, Sun M, Mochizuki A, Lee A, Odesa S, Billingslea-Yoon E, Moughon D, Wang A, Cloughesy T, Prins R, Liau L. ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION Neuro-Oncology. 20: vi10-vi10. DOI: 10.1093/Neuonc/Noy148.034  0.689
2018 Orpilla J, Mochizuki A, Reynoso J, Akkad N, Lee A, Davidson T, Liau L, Cloughesy T, Prins R. ATIM-25. NEOADJUVANT PD-1 ANTIBODY BLOCKADE IS ASSOCIATED WITH FOCAL UPREGULATION OF PD-L1 AND CD8 T CELL INFILTRATE IN RECURRENT GLIOBLASTOMA Neuro-Oncology. 20: vi6-vi6. DOI: 10.1093/Neuonc/Noy148.020  0.305
2018 Prins R, Mochizuki A, Orpilla J, Lee A, Davidson T, Gaffey S, Sanders C, Rytlewski J, Ellingson B, Li G, Yong W, Clarke J, Arrillaga-Romany I, Colman H, Reardon D, ... ... Liau L, et al. ATIM-12. NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY PROMOTES INTRATUMORAL AND SYSTEMIC IMMUNE RESPONSES IN RECURRENT GLIOBLASTOMA: AN IVY CONSORTIUM TRIAL Neuro-Oncology. 20: vi3-vi3. DOI: 10.1093/Neuonc/Noy148.007  0.369
2018 Mikkelsen T, Cloughesy T, Landolfi J, Vogelbaum M, Ostertag D, Elder J, Chen C, Kalkanis S, Kesari S, Lai A, Lee I, Liau L, Nghiemphu P, Piccioni D, Accomando W, et al. 25 Durable complete responses observed in patients with recurrent high grade glioma treated with Toca 511 & Toca FC Canadian Journal of Neurological Sciences / Journal Canadien Des Sciences Neurologiques. 45: S11-S11. DOI: 10.1017/Cjn.2018.290  0.455
2017 Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proceedings of the National Academy of Sciences of the United States of America. PMID 28874539 DOI: 10.1073/Pnas.1706689114  0.704
2017 Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro-Oncology. PMID 28115578 DOI: 10.1093/Neuonc/Now287  0.735
2017 Cloughesy TF, Ostertag D, Landolfi JC, Walbert T, Vogelbaum MA, Elder JB, Bloomfield S, Carter B, Chen C, Kalkanis SN, Kesari S, Lai A, Lee I, Liau LM, Mikkelsen T, et al. Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC. Journal of Clinical Oncology. 35: e13504-e13504. DOI: 10.1200/Jco.2017.35.15_Suppl.E13504  0.313
2017 Soto H, Antonios J, Everson R, Moughon D, Wang A, Orpilla J, Radu C, Ellingson B, Lee J, Cloughesy T, Phelps M, Czernin J, Liau L, Prins R. NIMG-36. DELINEATION OF IMMUNE RESPONSES AFTER IMMUNOTHERAPY IN GLIOBLASTOMA USING PET AND MRI Neuro-Oncology. 19: vi149-vi150. DOI: 10.1093/Neuonc/Nox168.611  0.688
2017 Lee A, Davidson T, Galvez M, Nathanson D, Wang A, Liau L, Prins R. IMMU-20. CHARACTERIZING THE IMMUNE LANDSCAPE OF PD-1/PD-L1 IN BRAIN TUMOR IMMUNE CELL POPULATION USING CyTOF MASS CyTOMETRY Neuro-Oncology. 19: vi116-vi116. DOI: 10.1093/Neuonc/Nox168.478  0.398
2017 Walbert T, Bota D, Vogelbaum M, Kalkanis S, Liau L, Mikkelsen T, Gruber H, Shorr J, Rodriguez-Aquirre M, Ostertag D, Mitchell L, Jolly D, Cloughesy T. ATIM-21. INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH HIGH GRADE GLIOMA RESULTS IN QUANTIFIABLE EXPRESSION OF CYTOSINE DEAMINASE IN TUMOR TISSUE Neuro-Oncology. 19: vi30-vi31. DOI: 10.1093/Neuonc/Nox168.116  0.396
2017 Walbert T, Bota D, Vogelbaum M, Kalkanis S, Liau L, Mikkelsen T, Gruber H, Shorr J, Rodriguez-Aguirre M, Ostertag D, Mitchell L, Jolly D, Cloughesy T. SCDT-06. QUANTIFIABLE LEVELS OF THE TRANSGENE, CYTOSINE DEAMINASE, IN TUMOR SAMPLES FOLLOWING INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 19: vi265-vi266. DOI: 10.1093/Neuonc/Nox168.1089  0.389
2016 Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. PD-1 blockade enhances the vaccination-induced immune response in glioma. Jci Insight. 1. PMID 27453950 DOI: 10.1172/Jci.Insight.87059  0.72
2016 Hsu M, Sedighim S, Wang T, Antonios JP, Everson RG, Tucker AM, Du L, Emerson R, Yusko E, Sanders C, Robins H, Yong WH, Davidson TB, Li G, Liau LM, et al. TCR sequencing can identify and track glioma-infiltrating T cells after DC vaccination. Cancer Immunology Research. PMID 26968205 DOI: 10.1158/2326-6066.Cir-15-0240  0.739
2016 Antonios J, Soto H, Everson R, Orpilla J, Shin N, Moughon D, Sedighim S, Treger J, Odesa S, Tucker A, Yong W, Cloughesy T, Prins R, Liau L. TMIC-16. TUMOR-INFILTRATING MYELOID CELLS MEDIATE ADAPTIVE IMMUNE RESISTANCE IN GLIOBLASTOMA Neuro-Oncology. 18: vi203-vi203. DOI: 10.1093/Neuonc/Now212.856  0.726
2016 Everson R, Shin N, Antonios J, Soto H, Tucker A, Zaretsky J, Orpilla J, Rathe S, Popescu F, Largaespada D, Liau L, Prins R. IMST-56. TUMOR LYSATE-PULSED DC VACCINATION INDUCES NEOANTIGEN-SPECIFIC T CELL RESPONSES Neuro-Oncology. 18: vi99-vi99. DOI: 10.1093/Neuonc/Now212.412  0.739
2016 Antonios J, Soto H, Everson R, Orpilla J, Shin N, Nathanson D, Harris R, Sadeghi S, Ellingson B, Liau L, Prins R. IMST-28. NON-INVASIVE IMMUNE MONITORING FOLLOWING DC VACCINATION EFFECTIVELY DELINEATES IMMUNE RESPONSES IN GLIOBLASTOMA Neuro-Oncology. 18: vi92-vi92. DOI: 10.1093/Neuonc/Now212.384  0.712
2016 Moughon D, Everson R, Odesa S, Soto H, Billingslea-Yoon E, Sedighim S, Orpilla J, Lin J, Prins R, Liau L. ATIM-32. PHASE IIA CLINICAL TRIAL EVALUATING DENDRITIC CELL VACCINE FOR THE TREATMENT OF LOW-GRADE GLIOMAS Neuro-Oncology. 18: vi25-vi25. DOI: 10.1093/Neuonc/Now212.097  0.377
2016 Davidson T, Hsu M, Sedighim S, Moughon D, Yong W, Liau L, Prins R. ATIM-26. PD-1 EXPRESSION BY TUMOR INFILTRATING LYMPHOCYTES IN GLIOBLASTOMA IS A MARKER OF BOTH ACTIVATION AND EXHAUSTION Neuro-Oncology. 18: vi23-vi23. DOI: 10.1093/Neuonc/Now212.091  0.387
2015 Reardon DA, Gilbert MR, Wick W, Liau L. Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. Neuro-Oncology. 17: vii32-vii40. PMID 26516225 DOI: 10.1093/Neuonc/Nov178  0.397
2015 Everson RG, Antonios JP, Lisiero DN, Soto H, Scharnweber R, Garrett MC, Yong WH, Li N, Li G, Kruse CA, Liau LM, Prins RM. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro-Oncology. PMID 26330563 DOI: 10.1093/Neuonc/Nov153  0.692
2015 Harris RJ, Cloughesy TF, Liau LM, Prins RM, Antonios JP, Li D, Yong WH, Pope WB, Lai A, Nghiemphu PL, Ellingson BM. pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro-Oncology. PMID 26113557 DOI: 10.1093/Neuonc/Nov106  0.608
2015 Antonios JP, Everson RG, Liau LM. Dendritic cell immunotherapy for brain tumors. Journal of Neuro-Oncology. 123: 425-32. PMID 26037466 DOI: 10.1007/S11060-015-1830-1  0.727
2015 Antonios J, Soto H, Orpilla J, Shin N, Everson R, Liau L, Prins R. Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P393  0.764
2015 Bosch M, Prins R, Liau L. Abstract 2491: Treatment with tumor lysate-pulsed autologous dendritic cells prolongs survival in patients with recurrent glioblastoma multiforme Cancer Research. 75: 2491-2491. DOI: 10.1158/1538-7445.Am2015-2491  0.399
2015 Antonios J, Soto H, Orpilla J, Shin N, Everson R, Liau L, Prins R. TMIC-04THERAPEUTIC ANTI-GLIOMA IMMUNITY IS DEPENDENT ON VACCINATION-INDUCED T CELL RESPONSES AND INHIBITION OF iAPC FUNCTION IN THE TUMOR MICROENVIRONMENT Neuro-Oncology. 17: v214.8-v215. DOI: 10.1093/Neuonc/Nov236.04  0.75
2015 Pelargos P, Qin Y, Voth B, Thill K, Chung L, Prins R, Liau L, Ung N, Hojat S, Yong W, Gordon L, Wadehra M, Yang I. MPTH-27A LARGE-SCALE UCLA GLIOMA TISSUE MICROARRAY IDENTIFIES EMP2 AS A NOVEL BIOMARKER FOR GBM THAT CORRELATES WITH OVERALL PROGNOSIS Neuro-Oncology. 17: v144.2-v144. DOI: 10.1093/Neuonc/Nov222.27  0.374
2015 Sedighim S, Hsu M, Antonios J, Emerson R, Yusko E, Sanders C, Davidson T, Liau L, Prins R. IMCT-11NEXT GENERATION T CELL RECEPTOR SEQUENCING CAN IDENTIFY, QUANTIFY, AND TRACK TUMOR-SPECIFIC T CELL POPULATIONS BEFORE AND AFTER DENDRITIC CELL VACCINATION IN GLIOBLASTOMA MULTIFORME PATIENTS Neuro-Oncology. 17: v109.4-v110. DOI: 10.1093/Neuonc/Nov218.11  0.751
2015 Hickey M, Soto H, Treger J, Erickson K, Malone C, Ha E, Young E, Prins R, Liau L, Kruse C. IMCT-10A PHASE I DOSE ESCALATION STUDY TO TEST THE SAFETY OF INTRATUMORAL ADOPTIVE IMMUNE THERAPY WITH AlloCTL IN RECURRENT GLIOMA PATIENTS Neuro-Oncology. 17: v109.3-v109. DOI: 10.1093/Neuonc/Nov218.10  0.393
2015 Kato Y, Scharnweber R, Inagaki A, Kamijima S, Hickey M, Lisiero D, Hermann K, Soto H, Antonios J, Sedighim S, Okada H, Liau L, Klatzmann D, Prins R, Kashara N. IMPS-19RETROVIRAL REPLICATING VECTOR-MEDIATED DELIVERY OF AN IMMUNODOMINANT NEO-ANTIGEN EPITOPE TARGET FOR VIRO-IMMUNOTHERAPY IN EXPERIMENTAL GLIOMA Neuro-Oncology. 17: v117.2-v117. DOI: 10.1093/Neuonc/Nov217.19  0.712
2015 Pelargos P, Qin Y, Voth B, Thill K, Chung L, Prins R, Liau L, Ung N, Hojat S, Yong W, Gordon L, Wadehra M, Yang I. ATPS-62TARGETING OF NOVEL GBM BIOMARKER EMP2 RESULTS IN DECREASED TUMOR GROWTH AND INCREASED TUMOR NECROSIS Neuro-Oncology. 17: v31.5-v32. DOI: 10.1093/Neuonc/Nov204.62  0.417
2014 Lisiero DN, Soto H, Everson RG, Liau LM, Prins RM. The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells. Journal For Immunotherapy of Cancer. 2: 8. PMID 25054063 DOI: 10.1186/2051-1426-2-8  0.332
2014 Everson RG, Jin RM, Wang X, Safaee M, Scharnweber R, Lisiero DN, Soto H, Liau LM, Prins RM. Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. Journal For Immunotherapy of Cancer. 2: 10. PMID 24883189 DOI: 10.1186/2051-1426-2-10  0.375
2014 Kruse C, Liau L, Prins R, Antonios J, Ha E, Kasahara N, Soto H, Yang I. Chronic inflammation drives glioma growth: cellular and molecular factors responsible for an immunosuppressive microenvironment Neuroimmunology and Neuroinflammation. 1: 66. DOI: 10.4103/2347-8659.139717  0.714
2014 Garrett MC, Mottahedeh J, Sperry J, Eskin A, Coppola G, Shih Y, Lai A, Chou A, Liau L, Prins R, Cloughesy T, Wu H, Nelson S, Kornblum H. Abstract 447: The IDH1 mutation in human glioblastoma and its effects on epigenetic modification and cell fate selection Cancer Research. 74: 447-447. DOI: 10.1158/1538-7445.Am2014-447  0.366
2014 Hardy A, Prins R, Kong X, Woodworth D, Pope W, Yong W, Cloughesy T, Liau L, Ellingson B. NI-32 * ENHANCING TUMOR RESPONSE USING QUANTITATIVE VOLUMETRY FROM T1 SUBTRACTION MAPS IN MALIGNANT GLIOMA TREATED WITH DENDRITIC CELL VACCINATION Neuro-Oncology. 16: v145-v145. DOI: 10.1093/Neuonc/Nou264.30  0.494
2014 Antonios J, Soto H, Harris R, Nathanson D, Sadeghi S, Ellingson B, Liau L, Prins R. IT-01 * PD1/PDL1 INTERACTIONS MEDIATE SUPPRESSION OF ANTI-TUMOR IMMUNE ACTIVITY IN GLIOMA Neuro-Oncology. 16: v110-v110. DOI: 10.1093/Neuonc/Nou258.1  0.73
2014 Harris R, Cloughesy T, Liau L, Lai A, Nghiemphu P, Li D, Pope W, Ellingson B. BI-10 * pH-WEIGHTED MRI IN HUMAN GLIOMAS Neuro-Oncology. 16: v25-v25. DOI: 10.1093/Neuonc/Nou239.10  0.38
2013 Lasky JL, Panosyan EH, Plant A, Davidson T, Yong WH, Prins RM, Liau LM, Moore TB. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Research. 33: 2047-56. PMID 23645755  0.377
2013 Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G, Cloughesy TF, Liau LM. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 152-7. PMID 23377664 DOI: 10.1097/Cji.0B013E3182811Ae4  0.376
2013 Morris LG, Kaufman AM, Gong Y, Ramaswami D, Walsh LA, Turcan ?, Eng S, Kannan K, Zou Y, Peng L, Banuchi VE, Paty P, Zeng Z, Vakiani E, Solit D, ... ... Liau L, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nature Genetics. 45: 253-61. PMID 23354438 DOI: 10.1038/Ng.2538  0.322
2013 Ellingson BM, Lai A, Harris RJ, Selfridge JM, Yong WH, Das K, Pope WB, Nghiemphu PL, Vinters HV, Liau LM, Mischel PS, Cloughesy TF. Probabilistic radiographic atlas of glioblastoma phenotypes. Ajnr. American Journal of Neuroradiology. 34: 533-40. PMID 22997168 DOI: 10.3174/Ajnr.A3253  0.316
2013 Liu Y, Zhang Y, Tso JL, Menjivar JC, Tian JY, Liau L, McBride W, Tso C. Abstract 3765: High-throughput RNAi screening identifies genes controlling glioblastoma stem cell migration and survival. Cancer Research. 73: 3765-3765. DOI: 10.1158/1538-7445.Am2013-3765  0.406
2012 Yang I, Jian Y, Garcia H, Choy W, Nagasawa DT, Spasic M, Trang A, Soto H, Ericcson K, Lisiero D, Hickey M, Kruse C, Prins RM, Rome L, Liau LM. 198 An Antigen Vault Nanoparticle Vaccine Can Effectively Stimulate Dendritic Cells and Activate a Specific T cell Immune Response. Neurosurgery. 71: E576-E577. PMID 28175807 DOI: 10.1227/01.neu.0000417788.76126.66  0.313
2012 Fong B, Jin R, Wang X, Safaee M, Lisiero DN, Yang I, Li G, Liau LM, Prins RM. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. Plos One. 7: e32614. PMID 22485134 DOI: 10.1371/Journal.Pone.0032614  0.313
2012 Nagasawa D, Spasic M, Choy W, Garcia H, Trang A, Shafa B, Duong D, Ausman J, Bergsneider M, Liau L, McBride D, Yang I. Analysis of 223 Brain Tumor Patients Treated at a Level 1 Trauma County Medical Center Journal of Neurological Surgery Part B: Skull Base. 73. DOI: 10.1055/S-0032-1312283  0.342
2011 Yamada K, Tso J, Ye F, Choe J, Liu Y, Liau LM, Tso CL. Essential gene pathways for glioblastoma stem cells: clinical implications for prevention of tumor recurrence. Cancers. 3: 1975-95. PMID 24212792 DOI: 10.3390/cancers3021975  0.356
2011 Konkankit VV, Kim W, Koya RC, Eskin A, Dam MA, Nelson S, Ribas A, Liau LM, Prins RM. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. Journal of Translational Medicine. 9: 192. PMID 22060015 DOI: 10.1186/1479-5876-9-192  0.381
2011 Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1603-15. PMID 21135147 DOI: 10.1158/1078-0432.Ccr-10-2563  0.425
2010 Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S. Genomic landscape of meningiomas. Brain Pathology (Zurich, Switzerland). 20: 751-62. PMID 20015288 DOI: 10.1111/J.1750-3639.2009.00356.X  0.337
2010 Kim W, Liau LM. Dendritic cell vaccines for brain tumors. Neurosurgery Clinics of North America. 21: 139-57. PMID 19944973 DOI: 10.1016/j.nec.2009.09.005  0.376
2009 Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America. 106: 9435-40. PMID 19478061 DOI: 10.1073/Pnas.0900571106  0.388
2008 Prins RM, Odesa S, Soto H, Yong WH, Lai A, Bosch M, Boynton A, Cloughesy TF, Liau LM. Autologous tumor-lysate pulsed dendritic cell vaccination, together with the TLR-7 agonist 5% imiquimod, and serum pro- inflammatory cytokine levels in glioblastoma patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 11021. PMID 27947675 DOI: 10.1200/Jco.2008.26.15_Suppl.11021  0.369
2008 Prins RM, Shu CJ, Radu CG, Vo DD, Khan-Farooqi H, Soto H, Yang MY, Lin MS, Shelly S, Witte ON, Ribas A, Liau LM. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunology, Immunotherapy : Cii. 57: 1279-89. PMID 18253732 DOI: 10.1007/S00262-008-0461-1  0.412
2008 Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. Plos Medicine. 5: e8. PMID 18215105 DOI: 10.1371/Journal.Pmed.0050008  0.315
2007 Liau LM, Prins RM, Odesa SK, Yang MY, Lin MS, Khan-Farooqi H, Soto H, Lai A, Bosch M, Boynton A, Cloughesy TF. Dendritic cell vaccination in combination with TLR-7 agonist, imiquimod, following radio-chemotherapy for newly diagnosed glioblastoma Journal of Clinical Oncology. 25: 2021-2021. DOI: 10.1200/jco.2007.25.18_suppl.2021  0.45
2006 Prins RM, Vo DD, Khan-Farooqi H, Yang MY, Soto H, Economou JS, Liau LM, Ribas A. NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. Journal of Immunology (Baltimore, Md. : 1950). 177: 8448-55. PMID 17142742  0.386
2006 Yang MY, Zetler PM, Prins RM, Khan-Farooqi H, Liau LM. Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications. Expert Review of Neurotherapeutics. 6: 1481-94. PMID 17078788 DOI: 10.1586/14737175.6.10.1481  0.384
2006 Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, Nelson SF. Primary glioblastomas express mesenchymal stem-like properties. Molecular Cancer Research : McR. 4: 607-19. PMID 16966431 DOI: 10.1158/1541-7786.MCR-06-0005  0.311
2006 Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, Lee Y, Dia EQ, Yoshimoto K, Mischel PS, Liau LM, Cloughesy TF, Nelson SF. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Research. 66: 159-67. PMID 16397228 DOI: 10.1158/0008-5472.CAN-05-0077  0.314
2006 Prins RM, Bruhn KW, Craft N, Lin JW, Kim CH, Odesa SK, Miller JF, Liau LM. Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden. Neurosurgery. 58: 169-78; discussion 1. PMID 16385341 DOI: 10.1227/01.Neu.0000192367.29047.64  0.402
2006 Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JF, Liau LM. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. Journal of Immunology (Baltimore, Md. : 1950). 176: 157-64. PMID 16365406 DOI: 10.4049/Jimmunol.176.1.157  0.454
2005 Khan-Farooqi HR, Prins RM, Liau LM. Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies. Neurological Research. 27: 692-702. PMID 16197806 DOI: 10.1179/016164105X49490  0.373
2005 Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5515-25. PMID 16061868 DOI: 10.1158/1078-0432.CCR-05-0464  0.435
2005 Craft N, Bruhn KW, Nguyen BD, Prins R, Lin JW, Liau LM, Miller JF. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. Journal of Immunology (Baltimore, Md. : 1950). 175: 1983-90. PMID 16034143 DOI: 10.4049/Jimmunol.175.3.1983  0.398
2004 Prins RM, Liau LM. Cellular immunity and immunotherapy of brain tumors. Frontiers in Bioscience : a Journal and Virtual Library. 9: 3124-36. PMID 15353342  0.398
2004 Prins RM, Liau LM. Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done Neuro-Oncology. 6: 265-266. DOI: 10.1215/S1152851703200077  0.327
2004 Chen C, Tao S, Shai R, Mischel P, Liau L, Pinta J, Horvath S, Nelson S, Sawyers C. 315 Molecular signature of the PTEN tumor suppressor-identification of IGFBP2 as a surrogate marker for PTEN/Akt signaling European Journal of Cancer Supplements. 2: 96. DOI: 10.1016/S1359-6349(04)80323-9  0.352
2003 Prins RM, Odesa SK, Liau LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Research. 63: 8487-91. PMID 14679014  0.353
2003 Broder H, Anderson A, Kremen TJ, Odesa SK, Liau LM. MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor. Journal of Neuro-Oncology. 64: 21-30. PMID 12952283 DOI: 10.1007/BF02700017  0.38
2002 Liau LM, Jensen ER, Kremen TJ, Odesa SK, Sykes SN, Soung MC, Miller JF, Bronstein JM. Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Research. 62: 2287-93. PMID 11956085  0.597
2000 Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L, Mischel PS, Belldegrun A, Cloughesy TF. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurgical Focus. 9: e8. PMID 16817691 DOI: 10.3171/foc.2000.9.6.9  0.622
2000 Broder H, Anderson A, Odesa SK, Kremen TJ, Liau LM. Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor. Neurosurgical Focus. 9: e6. PMID 16817689  0.393
2000 Liau LM, Lallone RL, Seitz RS, Buznikov A, Gregg JP, Kornblum HI, Nelson SF, Bronstein JM. Identification of a human glioma-associated growth factor gene, granulin, using differential immuno-absorption. Cancer Research. 60: 1353-60. PMID 10728698  0.518
1999 Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, Becker DP, Bronstein JM. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. Journal of Neurosurgery. 90: 1115-24. PMID 10350260 DOI: 10.3171/jns.1999.90.6.1115  0.606
1999 Liau LM, Fakhrai H, Black KL. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene. Neurological Research. 20: 742-7. PMID 9864741 DOI: 10.1080/01616412.1998.11740594  0.329
Show low-probability matches.